Cargando…

B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets

Increasing recognition of the role of B cells in the adaptive immune response makes B cells an important therapeutic target in autoimmunity. Numerous current and developmental immunotherapies target B cells for elimination through recognition of cell-surface proteins expressed specifically on B cell...

Descripción completa

Detalles Bibliográficos
Autores principales:	Forsthuber, Thomas G., Cimbora, Daniel M., Ratchford, John Nolan, Katz, Eliezer, Stüve, Olaf
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5865455/ https://www.ncbi.nlm.nih.gov/pubmed/29593838 http://dx.doi.org/10.1177/1756286418761697

Ejemplares similares

CD11c(+)CD88(+)CD317(+) myeloid cells are critical mediators of persistent CNS autoimmunity
por: Manouchehri, Navid, et al.
Publicado: (2021)

Targeting “bad” B cells in multiple sclerosis: Could laquinimod be part of the armamentarium?
por: Forsthuber, Thomas G., et al.
Publicado: (2016)

Intrathecal anti-CD20 efficiently depletes meningeal B cells in CNS autoimmunity
por: Lehmann-Horn, Klaus, et al.
Publicado: (2014)

B-cell–targeted therapies in relapsing forms of MS
por: Dubey, Divyanshu, et al.
Publicado: (2017)

Functional characterization of reappearing B cells after anti-CD20 treatment of CNS autoimmune disease
por: Häusler, Darius, et al.
Publicado: (2018)

Memory CD4(+) T Cells in Immunity and Autoimmune Diseases
por: Raphael, Itay, et al.
Publicado: (2020)

Distinctive transcriptomic and epigenomic signatures of bone marrow-derived myeloid cells and microglia in CNS autoimmunity
por: Manouchehri, Navid, et al.
Publicado: (2023)

Is intrathecal anti-CD20 an option to target compartmentalized CNS inflammation in progressive MS?
por: Weber, Martin S.
Publicado: (2015)

PEG Minocycline-Liposomes Ameliorate CNS Autoimmune Disease
por: Hu, Wei, et al.
Publicado: (2009)

Ectopic Lymphoid Follicles in Multiple Sclerosis: Centers for Disease Control?
por: Negron, Austin, et al.
Publicado: (2020)

Therapeutic targeting of STAT pathways in CNS autoimmune diseases
por: Egwuagu, Charles E., et al.
Publicado: (2013)

CNS Intravascular Lymphoma: A Case Report
por: Awad, Amer, et al.
Publicado: (2011)

Generation of CD20-specific TCRs for TCR gene therapy of CD20(low) B-cell malignancies insusceptible to CD20-targeting antibodies
por: Jahn, Lorenz, et al.
Publicado: (2016)

The neonatal CNS is not conducive for encephalitogenic Th1 T cells and B cells during experimental autoimmune encephalomyelitis
por: Cravens, Petra D, et al.
Publicado: (2013)

Therapeutic approaches targeting CD95L/CD95 signaling in cancer and autoimmune diseases
por: Risso, Vesna, et al.
Publicado: (2022)

Chemokine-Driven Migration of Pro-Inflammatory CD4(+) T Cells in CNS Autoimmune Disease
por: Heng, Aaron H. S., et al.
Publicado: (2022)

Differential effects of anti-CD20 therapy on CD4 and CD8 T cells and implication of CD20-expressing CD8 T cells in MS disease activity
por: Shinoda, Koji, et al.
Publicado: (2023)

CD19 and CD20 Targeted Vectors Induce Minimal Activation of Resting B Lymphocytes
por: Kneissl, Sabrina, et al.
Publicado: (2013)

CD200 in CNS tumor-induced immunosuppression: the role for CD200 pathway blockade in targeted immunotherapy
por: Moertel, Christopher L, et al.
Publicado: (2014)

The regulation and function of CD20: an “enigma” of B-cell biology and targeted therapy
por: Pavlasova, Gabriela, et al.
Publicado: (2020)

The dual role of CD6 as a therapeutic target in cancer and autoimmune disease
por: Gurrea-Rubio, Mikel, et al.
Publicado: (2022)

Combination Treatment With Anti-CD20 and Oral Anti-CD3 Prevents and Reverses Autoimmune Diabetes
por: Hu, Changyun, et al.
Publicado: (2013)

Monoclonal antibodies targeting CD20
por: Chang, Chien-Hsing, et al.
Publicado: (2013)

Targeting CD22 Reprograms B-Cells and Reverses Autoimmune Diabetes
por: Fiorina, Paolo, et al.
Publicado: (2008)

COVID‐19 vaccine‐readiness for anti‐CD20‐depleting therapy in autoimmune diseases
por: Baker, D., et al.
Publicado: (2020)

Characterization of the canine CD20 as a therapeutic target for comparative passive immunotherapy
por: Dias, Joana N. R., et al.
Publicado: (2022)

United we stand: Double targeting of CD79B and CD20 in diffuse large B‐cell lymphoma
por: Tarantelli, Chiara, et al.
Publicado: (2022)

Therapeutic Potential of Hyporesponsive CD4(+) T Cells in Autoimmunity
por: Maggi, Jaxaira, et al.
Publicado: (2015)

Toll-Like Receptor Homolog CD180 Expression Is Diminished on Natural Autoantibody-Producing B Cells of Patients with Autoimmune CNS Disorders
por: Hayden, Zsófia, et al.
Publicado: (2021)

Targeting the CD40-CD154 Signaling Pathway for Treatment of Autoimmune Arthritis
por: Lai, Jenn-Haung, et al.
Publicado: (2019)

CD4(+)CD25(+) T-Cells Control Autoimmunity in the Absence of B-Cells
por: Mariño, Eliana, et al.
Publicado: (2009)

Targeting endothelial CD146 attenuates neuroinflammation by limiting lymphocyte extravasation to the CNS
por: Duan, Hongxia, et al.
Publicado: (2013)

Differentiation and Transmigration of CD4 T Cells in Neuroinflammation and Autoimmunity
por: Sonar, Sandip Ashok, et al.
Publicado: (2017)

B-Cell Targeted Treatments for Neuromyelitis Optica Spectrum Disorder: A Focus on CD19 and CD20
por: Levy, Michael, et al.
Publicado: (2021)

Development of a Bispecific Nanobody Targeting CD20 on B-Cell Lymphoma Cells and CD3 on T Cells
por: Liu, Yanlong, et al.
Publicado: (2022)

Response to: Monoclonal antibodies targeting CD20
por: Klein, Christian, et al.
Publicado: (2013)

Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment
por: Du, Fanny Huynh, et al.
Publicado: (2017)

Review of an Anti-CD20 Monoclonal Antibody for the Treatment of Autoimmune Diseases of the Skin
por: Ly, Sophia, et al.
Publicado: (2023)

Longitudinal COVID-19 immune trajectories in patients with neurological autoimmunity on anti-CD20 therapy
por: Bazzi, Sam A., et al.
Publicado: (2022)

Blunted Post-COVID-19 Humoral Immunity in Patients With CNS Demyelinating Disorders on Anti-CD20 Treatments
por: Money, Kelli M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rn8kgcbrq1j3g4tueia2fnlmsm